Setback for Boston Scientific
This article was originally published in The Silver Sheet
Executive Summary
Just as Boston Scientific was beginning to emerge from the quality control cloud it had been living under for the past couple years, FDA revealed Aug. 14 that the firm had initiated a Class I recall of its NexStent carotid artery stenting system. The company, which began the recall June 6, says it received complaints regarding detachment of the tip of the delivery system during the stenting procedure. Boston Scientific has taken extensive steps to revamp its quality systems in the wake of a January 2006 corporate warning letter ("The Silver Sheet" August 2008)
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.